Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Akamis Bio.

    Client Virtual Booth

    AKAMIS BIO

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Akamis Bio
    unitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    4-10, The Quadrant, Abingdon Science Park, Barton Lane, Abingdon, Oxfordshire, OX14 3YS
    Telephone
    Telephone
    +44 (0)1235 835328
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.akamisbio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/akamisbio/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Akamis Bio Announces $30 Million Financing, Provides Clinical Program Update and Relaunches with Name Change from PsiOxus Therapeutics

    Details:

    The net proceeds will fund development activities for the clinical stage NG-350A and NG-641 programs, as well as general corporate purposes. NG-350A is oncolytic adenoviral vector which expresses a full length agonist anti-CD40 antibody at the site of virus replication.


    Lead Product(s): NG-350A

    Therapeutic Area: Oncology Product Name: NG-350A

    Highest Development Status: Phase IProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Undisclosed

    Deal Size: $30.0 million Upfront Cash: Undisclosed

    Deal Type: Financing January 06, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    PsiOxus and Bluebird Bio Present Novel Data Combining PsiOxus T-SIGn Platform with CAR-T Therapy to Clear Primary Tumors and Metastases

    Details:

    The study showed that when injected intravenously into mice with established human tumor xenografts, PsiOxus’ armed T-SIGn vectors reprogrammed the tumor microenvironment to a proinflammatory state.


    Lead Product(s): Anti-EGFR CAR-T therapy,NG-347,NG-641

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Bluebird Bio

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 14, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    PsiOxus Therapeutics Updates Agreement with Bristol Myers Squibb to Advance their Clinical Stage Immuno-Oncology Collaboration

    Details:

    The first stage of this collaboration combined Bristol Myers Squibb’s Opdivo with PsiOxus’ enadenotucirev in the Phase 1 SPICE study to determine the safety and tolerability of combining these two agents, and to optimise the combination intravenous dosing regimen.


    Lead Product(s): NG-641,Nivolumab

    Therapeutic Area: Oncology Product Name: NG-641

    Highest Development Status: IND EnablingProduct Type: Large molecule

    Recipient: Bristol Myers Squibb

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration April 07, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    PsiOxus Therapeutics Announces Clinical Trial with Third Cancer Gene Therapy Treatment

    Details:

    This is the first time that a tumor-specific virus containing four different therapeutic transgenes has been administered to cancer patients.


    Lead Product(s): NG-641

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: Phase IProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 05, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search